Literature DB >> 24907151

Identification of relapse predictors in IgG4-related disease using multivariate analysis of clinical data at the first visit and initial treatment.

Motohisa Yamamoto1, Masanori Nojima2, Hiroki Takahashi2, Yoshihiro Yokoyama2, Keisuke Ishigami2, Hidetaka Yajima2, Yui Shimizu2, Tetsuya Tabeya2, Mikiko Matsui2, Chisako Suzuki2, Yasuyoshi Naishiro2, Ken-ichi Takano2, Tetsuo Himi2, Kohzoh Imai2, Yasuhisa Shinomura2.   

Abstract

OBJECTIVES: Inducting clinical remission by glucocorticoid treatment is relatively easy in IgG4-related disease (IgG4-RD), but relapse also occurs easily with tapering of the steroid dose. The present study tried to analyse the cases to extract predictors of relapse present at the diagnosis of IgG4-RD.
METHODS: Subjects comprised 79 patients with IgG4-related dacryoadenitis and sialadenitis, known as Mikulicz's disease, who were diagnosed between April 1997 and October 2013 and followed-up for >2 years from the initial induction treatment. They were applied to Cox proportional hazard modelling, based on the outcome of interval to relapse. We performed multivariate analysis for the clinical factors of these cases and identified predictors of relapse.
RESULTS: Identified factors were male sex and younger onset in cases without organ involvement at diagnosis and low levels of serum IgG4 in cases with organ dysfunction at diagnosis. Complication with autoimmune pancreatitis and low steroid dose at initial treatment also tended to be associated with recurrence.
CONCLUSION: Follow-up is important in cases with recognized risk factors for relapse, including male sex and younger onset in cases without organ damage.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  IgG4-related disease; Mikulicz’s disease; autoimmune pancreatitis; multivariate analysis; relapse

Mesh:

Substances:

Year:  2014        PMID: 24907151     DOI: 10.1093/rheumatology/keu228

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  12 in total

1.  Predictors of disease relapse in IgG4-related disease following rituximab.

Authors:  Zachary S Wallace; Hamid Mattoo; Vinay S Mahajan; Maria Kulikova; Leo Lu; Vikram Deshpande; Hyon K Choi; Shiv Pillai; John H Stone
Journal:  Rheumatology (Oxford)       Date:  2016-02-16       Impact factor: 7.580

Review 2.  IgG4-related autoimmune diseases: Polymorphous presentation complicates diagnosis and treatment.

Authors:  Alexander Kleger; Thomas Seufferlein; Martin Wagner; Andrea Tannapfel; Thomas K Hoffmann; Julia Mayerle
Journal:  Dtsch Arztebl Int       Date:  2015-02-20       Impact factor: 5.594

Review 3.  IgG4-Related Ophthalmic Disease: Pooling of Published Cases and Literature Review.

Authors:  Albert Wu; Nicholas H Andrew; Alan A McNab; Dinesh Selva
Journal:  Curr Allergy Asthma Rep       Date:  2015-06       Impact factor: 4.806

4.  IgG4-related disease in an adolescent with radiologic-pathologic correlation.

Authors:  Renato Cesar Ferreira da Silva; Scott M Lieberman; Henry T Hoffman; Bruno Policeni; Amani Bashir; Richard J H Smith; T Shawn Sato
Journal:  Radiol Case Rep       Date:  2016-12-07

5.  Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients.

Authors:  Mikael Ebbo; Aurélie Grados; Maxime Samson; Matthieu Groh; Anderson Loundou; Aude Rigolet; Benjamin Terrier; Constance Guillaud; Clarisse Carra-Dallière; Frédéric Renou; Agnieszka Pozdzik; Pierre Labauge; Sylvain Palat; Jean-Marie Berthelot; Jean-Loup Pennaforte; Alain Wynckel; Céline Lebas; Noémie Le Gouellec; Thomas Quémeneur; Karine Dahan; Franck Carbonnel; Gaëlle Leroux; Antoinette Perlat; Alexis Mathian; Patrice Cacoub; Eric Hachulla; Nathalie Costedoat-Chalumeau; Jean-Robert Harlé; Nicolas Schleinitz
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240

6.  Factors in glucocorticoid regimens associated with treatment response and relapses of IgG4-related disease: a multicentre study.

Authors:  Mirei Shirakashi; Hajime Yoshifuji; Yuzo Kodama; Tsutomu Chiba; Motohisa Yamamoto; Hiroki Takahashi; Kazushige Uchida; Kazuichi Okazaki; Tetsuya Ito; Shigeyuki Kawa; Kazunori Yamada; Mitsuhiro Kawano; Shintaro Hirata; Yoshiya Tanaka; Masafumi Moriyama; Seiji Nakamura; Terumi Kamisawa; Shoko Matsui; Hiroto Tsuboi; Takayuki Sumida; Motoko Shibata; Hiroshi Goto; Yasuharu Sato; Tadashi Yoshino; Tsuneyo Mimori
Journal:  Sci Rep       Date:  2018-07-06       Impact factor: 4.379

7.  Retrospective single-centre analysis of IgG4-related disease patient population and treatment outcomes between 2007 and 2017.

Authors:  Chan Mi Lee; Mohamed Alalwani; Richard A Prayson; Carmen E Gota
Journal:  Rheumatol Adv Pract       Date:  2019-05-06

Review 8.  Therapeutic approach to IgG4-related disease: A systematic review.

Authors:  Pilar Brito-Zerón; Belchin Kostov; Xavier Bosch; Nihan Acar-Denizli; Manuel Ramos-Casals; John H Stone
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

9.  Differences and similarities between IgG4-related disease with and without dacryoadenitis and sialoadenitis: clinical manifestations and treatment efficacy.

Authors:  Mu Wang; Panpan Zhang; Wei Lin; Yunyun Fei; Hua Chen; Jing Li; Li Zhang; Wenjie Zheng; Yongze Li; Xiaofeng Zeng; Jiaxin Zhou; Yamin Lai; Xiaowei Liu; Huadan Xue; Yueying Cui; Lian Zhou; Jizhi Zhao; Wen Zhang
Journal:  Arthritis Res Ther       Date:  2019-02-01       Impact factor: 5.156

Review 10.  Renal Involvement in Retroperitoneal Fibrosis: Prevalence, Impact and Management Challenges.

Authors:  Ichiro Mizushima; Mitsuhiro Kawano
Journal:  Int J Nephrol Renovasc Dis       Date:  2021-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.